Patents by Inventor Eva Röijer

Eva Röijer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS OF USE FOR DETERMINATION OF HE4a
    Publication number: 20200325215
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Application
    Filed: July 1, 2020
    Publication date: October 15, 2020
    Applicants: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Ingegerd HELLSTROM, Karl-Erik HELLSTROM, John RAYCRAFT, Christian FERMÉR, Eva RÖIJER
  • COMPOSITIONS AND METHODS OF USE FOR DETERMINATION OF HE4a
    Publication number: 20180057575
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Application
    Filed: October 19, 2017
    Publication date: March 1, 2018
    Applicants: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.
    Inventors: Ingegerd HELLSTROM, Karl-Erik HELLSTROM, John RAYCRAFT, Christian FERMÉR, Eva RÖIJER
  • COMPOSITIONS AND METHODS OF USE FOR DETERMINATION OF HE4a
    Publication number: 20150353629
    Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.
    Type: Application
    Filed: February 17, 2011
    Publication date: December 10, 2015
    Inventors: Ingegerd Hellstrom, Karl-Erik Hellstrom, John Raycraft, Christian Fermér, Eva Röijer